Indication
Mycosis fungoides
Mycosis fungoides is an extranodal non-Hodgkin lymphoma and the most common form of primary cutaneous T-cell lymphoma. Read more about Mycosis fungoides
421 drugs 196 manufacturers
Drugs that treat it
Common Mycosis fungoides therapies.
OPZELURA (vinblastine sulfate)
DEXAMETHASONE
CYCLOPHOSPHAMIDE
CORTISONE ACETATE
DEXAMETHASONE SODIUM PHOSPHATE
METHYLPREDNISOLONE ACETATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonMycosis fungoides is an extranodal non-Hodgkin lymphoma and the most common form of primary cutaneous T-cell lymphoma.
It predominantly affects adults—most frequently presenting in older individuals—and arises from the malignant proliferation and epidermotropism of mature skin-homing memory T lymphocytes.
The disease characteristically exhibits an indolent clinical course that evolves through distinct cutaneous stages, progressing from persistent erythematous patches to infiltrated plaques, and potentially to cutaneous tumors, generalized erythroderma, or systemic dissemination to lymph nodes and visceral organs.
- medlineplus.gov
Mycosis fungoides is an extranodal non-Hodgkin lymphoma and the most common form of primary cutaneous T-cell lymphoma It predominantly affects adults—most frequently presenting in older individuals—and arises from the malignant proliferation and epidermotropism of mature skin-homing memory T lymphocytes The disease characteristically exhibits an indolent clinical course that evolves through distinct cutaneous stages, progressing from persistent erythematous patches to infiltrated plaques, and po...
- nih.gov
Mycosis fungoides is an extranodal non-Hodgkin lymphoma and the most common form of primary cutaneous T-cell lymphoma It predominantly affects adults—most frequently presenting in older individuals—and arises from the malignant proliferation and epidermotropism of mature skin-homing memory T lymphocytes
- nih.gov
The disease characteristically exhibits an indolent clinical course that evolves through distinct cutaneous stages, progressing from persistent erythematous patches to infiltrated plaques, and potentially to cutaneous tumors, generalized erythroderma, or systemic dissemination to lymph nodes and visceral organs
- nih.gov
The disease characteristically exhibits an indolent clinical course that evolves through distinct cutaneous stages, progressing from persistent erythematous patches to infiltrated plaques, and potentially to cutaneous tumors, generalized erythroderma, or systemic dissemination to lymph nodes and visceral organs
Personalize your experience
Follow Mycosis fungoides and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.